Paulson Capital (Delaware) Corp. Announces Meeting Date and Record Date for the Special Meeting of Stockholders

Paulson Capital (Delaware) Corp. Announces Meeting Date and Record Date for
the Special Meeting of Stockholders

PORTLAND, Ore., June 24, 2014 (GLOBE NEWSWIRE) -- Paulson Capital (Delaware)
Corp. (Nasdaq:PLCC) ("Paulson") today announced that a Special Meeting of
Stockholders will be held on July 14, 2014, at 1:00 p.m., PDT, at the offices
of Holland & Knight LLP, 111 S.W. Fifth Avenue, 2300 U.S. Bancorp Tower,
Portland, Oregon 97204. Holders of record of Paulson's common stock, as
reflected on the stock transfer books of Paulson, at the close of business on
June 25, 2014 (the "Record Date"), will be entitled to notice of and to vote
at the meeting.

As described in more detail in the Proxy Statement that will be mailed to
holders of record of Paulson's common stock as of the Record Date,
stockholders of Paulson will be asked to consider and vote upon, among other
matters, a proposal to approve the issuance of Paulson's common stock in
connection with the merger contemplated by the Agreement and Plan of Merger
dated May 8, 2014 (the "Merger Agreement"), among Paulson, Variation
Biotechnologies (US), Inc., a privately held Delaware corporation ("VBI"), and
VBI Acquisition Corp., a Delaware corporation and wholly owned subsidiary of
Paulson, and the corresponding change of control of Paulson. Under the Merger
Agreement, VBI will become the operating subsidiary of Paulson and VBI's
pre-merger stockholders will acquire shares of Paulson's common stock that
will represent approximately 59% of the outstanding voting power of Paulson's
capital stock upon consummation of the transactions contemplated by the Merger
Agreement, including a concurrent private placement of Paulson's common stock
with gross proceeds of at least $11,000,000 to certain institutional
stockholders of VBI and an additional institutional investor that has been
identified. Upon completion of the merger, Paulson will be renamed VBI
Vaccines, Inc.

The merger is subject to certain conditions, in addition to the approval by
the Paulson stockholders at the Special Meeting, that must be satisfied before
the merger is consummated. These conditions include, but are not limited to,
the approval by The NASDAQ Stock Market of the initial listing of the stock of
VBI Vaccines, Inc. on The NASDAQ Capital Market, and approval by FINRA of the
contemplated divestiture by Paulson of its operating subsidiary, Paulson
Investment Company, Inc. ("PIC"). There can be no assurance that these and
other conditions to the consummation of the merger will be satisfied even if
the Paulson stockholders approve the merger.

About Paulson Capital (Delaware) Corp.

Paulson Capital (Delaware) Corp. is a holding company founded in 1970 whose
operating subsidiary, PIC, is a boutique investment banking firm through which
substantially all of Paulson's business has been conducted. PIC has served as
a regional, full-service investment bank, underwriter and placement agent for
small-cap and emerging growth issuers. PIC currently maintains offices in
Portland, San Francisco, and New York. Paulson's shares trade on The NASDAQ
Capital Market under the symbol PLCC. For more information on Paulson, please
visit its Web site at http://www.paulsoninvestment.com.

This press release may contain certain "forward-looking statements'' within
the meaning of the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements are based on management's estimates,
assumptions, and projections, and are subject to uncertainties, many of which
are beyond the control of Paulson. Actual results may differ materially from
those anticipated in any forward-looking statement. Factors that may cause
such differences include the risks that (a) there may be regulatory or
litigation obstacles to completing the merger, or stockholders of Paulson may
not approve the merger, (b) The NASDAQ Capital Market may not accept the
shares of the merged company for listing, (c) potential products that appear
promising to VBI cannot be shown to be efficacious or safe in subsequent
preclinical or clinical trials, (d) VBI will not obtain appropriate or
necessary governmental approvals to market these or other potential products,
(e) VBI may not be able to obtain anticipated funding for their development
projects or other needed funding, and (f) VBI may not be able to secure or
enforce adequate legal protection, including patent protection, for its
products.

More detailed information about Paulson and risk factors that may affect the
realization of forward-looking statements, including the forward-looking
statements in this press release, is set forth in Paulson's filings with the
Securities and Exchange Commission. Paulson urges investors and security
holders to read those documents free of charge at the Commission's Web site
athttp://www.sec.gov. Interested parties may also obtain those documents free
of charge from Paulson. Forward-looking statements speak only as to the date
they are made, and except for any obligation under the U.S. federal securities
laws, Paulson undertakes no obligation to publicly update any forward-looking
statement as a result of new information, future events or otherwise.

CONTACT: Trent Davis, President
         (503) 243-6000
 
Press spacebar to pause and continue. Press esc to stop.